Preparation, characterization and in vitro anticoagulation of emodin-eluting controlled biodegradable stent coatings

Colloids and Surfaces B: Biointerfaces

Volumn 77, Issue 2, 2010, Pages 155-160

  Pan, Chang Jiang ^a   Wang, Jin ^b   Huang, Nan ^b  

^a CHONGQING UNIVERSITY   (China)

^b SOUTHWEST JIAOTONG UNIVERSITY   (China)

Author keywords

Anticoagulation; Drug release; Drug eluting stent; Emodin

Indexed keywords

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ADSORPTION PEAKS; ANTI-COAGULATION; BALLOON EXPERIMENT; BIODEGRADABLE STENTS; BLOOD COMPATIBILITY; BURST RELEASE; CARDIO-VASCULAR DISEASE; DRUG RELEASE; DRUG-ELUTING STENTS; FOURIER TRANSFORM INFRARED SPECTRA; FTIR; IN-VITRO; PLATELET ADHESION; POLY-LACTIDE-CO-GLYCOLIDE; POTENTIAL APPLICATIONS; STAINLESS STEEL SURFACE;

ADSORPTION; ARTIFICIAL ORGANS; BLOOD SUBSTITUTES; COATINGS; CONTROLLED DRUG DELIVERY; DRUG DOSAGE; EXPERIMENTS; FILM PREPARATION; FOURIER TRANSFORM INFRARED SPECTROSCOPY; PLASTIC FILMS; SPECTROSCOPY; STEEL CORROSION;

STAINLESS STEEL;

EMODIN; POLYGLACTIN; STAINLESS STEEL; BIOMATERIAL; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ADSORPTION KINETICS; ANTICOAGULATION; ARTICLE; BALLOON DILATATION; BARE METAL STENT; BIODEGRADABILITY; BLOOD COMPATIBILITY; CARDIOVASCULAR DISEASE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG STRUCTURE; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; MATERIAL COATING; MECHANICAL STRESS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SURFACE PROPERTY; THROMBOCYTE ADHESION; THROMBOCYTE POOR PLASMA; ADSORPTION; CHEMICAL MODEL; CHEMISTRY; DRUG DELIVERY SYSTEM; IN VITRO STUDY; METABOLISM; PROCEDURES; STENT;

ADSORPTION; CARDIOVASCULAR DISEASES; COATED MATERIALS, BIOCOMPATIBLE; DRUG DELIVERY SYSTEMS; EMODIN; HUMANS; LACTIC ACID; MODELS, CHEMICAL; PARTIAL THROMBOPLASTIN TIME; PLATELET ADHESIVENESS; POLYGLYCOLIC ACID; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; STAINLESS STEEL; STENTS; SURFACE PROPERTIES; IN VITRO TECHNIQUES;

EID: 77950857601     PISSN: 09277765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2010.01.019     Document Type: Article

References (32)

1. Landau C., Lange R.A., Hillis L.D. Percutaneous transluminal coronary angioplasty. N. Engl. J. Med. 1994, 330:981-993.
2. Hoeven B.L., Pires N.M.M., Warda H.M., et al. Drug-eluting stents:results, promises and problems. Int. J. Cardiol. 2005, 99:9-17.
3. Garas S.M., Huber P., Scott N.A. Overview of therapies for prevention of restenosis after coronary interventions. Pharm. Ther. 2001, 92:165-178.
4. Kimura T., Abe K., Shizuta S., et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 2002, 105:2986-2991.
5. Chung M., Gold H.K., Schwartz S.M., et al. Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. J. Am. Coll. Cardiol. 2002, 40:2072-2081.
6. Ferns G.A., Avades T.Y. The mechanisms of coronary restenosis: insights from experimental models. J. Exp. Pathol. 2000, 81:63-88.
7. Marx S.O., Jayaraman T., Go L.O., et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular muscle cells. Circ. Res. 1995, 76:412-417.
8. Poon M., Marx S.O., Gallo R., et al. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 1996, 98:2277-2283.
9. Gregory C.R., Huang X.F., Pratt R.E., et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995, 59:655-661.
10. Gallo R., Padurean A., Jayaraman T., et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999, 99:2164-2170.
11. Axel Dl, Kunert W., Göggelmann C., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997, 96:636-645.
12. Carter A.J., Aggarwal, Kopia G.A., et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res. 2004, 63:617-624.
13. Farb A., Heller P.F., Shroff S., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001, 104:473-479.
14. Huang H.C., Lee C.R., Chao P.D., et al. Vasorelaxant effect of emodin, an anthraquinone from a Chinese herb. Eur. J. Pharmacol. 1991, 205:289-294.
15. Kuo Y.C., Meng H.C., Tsai W.J. Regulation of cell proliferation, inflammatory cytokine production and calcium mobilization in primary human T lymphocytes by emodin from Polygonum hypoleucum Ohwi. Inflamm. Res. 2001, 50:73-82.
16. Lin C.C., Chang C.H., Yang J.J., Namba T., Hattori M. Hepatoprotective effects of emodin from Ventilago leiocarpa. J. Ethnopharmacol. 1996, 52:107-111.
17. Chang C.J., Ashendel C.L., Geahlen R.L., et al. Oncogene signal transduction inhibitors from medicinal plants. In Vivo 1996, 10:185-190.
18. Jayasuriya H., Koonchanok N.M., Geahlen R.L., et al. Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J. Nat. Prod. 1992, 55:696-698.
19. Zhang L., Chang C.J., Bacus S.S., Hung M.C. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 1995, 55:3890-3896.
20. Chan T.C., Chang C.J., Koonchanok N.M., Geahlen R.L. Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-tyrosine kinase inhibitor. Biochem. Biophys. Res. Commun. 1993, 193:1152-1158.
21. Li Z.G., Wang Z.Y., Liu S.Q. Possible way of emodin influencing the proliferation of rabbit aortic smooth muscle cells ex vivo. Chin. J. Clin. Rehabil. 2005, 9:134-135.
22. Pan H., Ge J.B., Wang K.Q., Liu X.B., Zhang H.Q., Wang X.F. Effect of emodin on the expression of cyclin D1 of human vascular smooth muscle cells. Chin. J. Intervent. Cardiol. 2005, 13:37-40.
23. Huang Z.D., Jiang M.L., Yi Y.K., Zeng R., Huang Y., Wu P. Effects of processed radix salvia miltiorrhizae and radix et rhizome rhei with wine on functions of blood platelet and anticoagulation of rat. Chin. Trad. Patent Med. 2001, 23:341-342.
24. Pan C.J., Tang J.J., Weng Y.J., et al. Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents. J. Control. Release 2006, 116:42-49.
25. Frank A., Subbu S.V., Santosh K.R., Freddy B. In vitro study of release mechanisms of paclitaxel and rapamycin from drug-incorporated biodegradable stent matrices. J. Control. Release 2004, 98:67-74.
26. Ranade S.V., Miller K.M., Richard R.E., et al. Physical characterization of controlled release of paclitaxel from the TAXUSTM Express2TM drug-eluting stent. J. Biomed. Mater. Res. 2004, 71A:625-634.
27. Pan C.J., Tang J.J., Weng Y.J., et al. Preparation and in vitro release profiles of drug-eluting controlled biodegradable polymer coating stents. Colloids Surf. B: Biointerfaces 2009, 73:199-206.
28. Pan C.J., Tang J.J., Weng Y.J., et al. Preparation and characterization of rapamycin-loaded PLGA coating stent. J. Mater. Sci.: Mater. Med. 2007, 18:2193-2198.
29. Suggs L.J., West J.L., Mikos A.G. Platelet adhesion on a bioresorbable poly(propylene fumarate-co-ethylene glycol) copolymer. Biomaterials 1999, 20:683-690.
30. Gorbet M.B., Sefton M.V. Biomaterials-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004, 25:5681-5703.
31. Tsai W.B., Grunkemeier J.M., Horbett T.A. Human plasma fibrinogen adsorption and platelet adhesion to polystyrene. J. Biomed. Mater. Res. 1999, 44:130-139.
32. He M., Xia Z.N., Yin Y.G., et al. Research on interactions between effective multicomponents of Radix et Rhizoma Rhei with bovine serum albumin by ultraviolet-visible spectra analysis. Chin. J. MAP 2004, 21:429-432.